OLYMPUS

Erik DiGiacomo Appointed General Manager of Olympus

Retrieved on: 
Tuesday, October 31, 2023
Professional Services, Data Management, Security, Technology, Software, Finance, Fintech, Capital Group Companies, OLYMPUS, Economics, News, Multimedia, Data management, CLO, Broadridge Financial Solutions, JPMorgan Chase, Lisp (programming language), L.L.C, Cornell University, Olympus, Virtusa, Software as a service, Security (finance)

Webonise US, LLC (“Webonise” or the “Company”), a global technology product development and digital solutions company that builds capabilities to enable businesses to thrive, today announced the appointment of Erik DiGiacomo as General Manager of a core product line, Olympus Fintech, LLC (“Olympus”), a cloud-based fintech platform of tools powered by Webonise that collateralized loan obligation (CLO), debt, and private equity fund managers use to improve performance.

Key Points: 
  • Webonise US, LLC (“Webonise” or the “Company”), a global technology product development and digital solutions company that builds capabilities to enable businesses to thrive, today announced the appointment of Erik DiGiacomo as General Manager of a core product line, Olympus Fintech, LLC (“Olympus”), a cloud-based fintech platform of tools powered by Webonise that collateralized loan obligation (CLO), debt, and private equity fund managers use to improve performance.
  • As General Manager, Mr. DiGiacomo will be responsible for leading the go-to-market strategy and spearheading upcoming launches of Olympus’ newest products.
  • “I am excited to lead Olympus’ next phase of development and support the launch of several innovative products in 2024,” Mr. DiGiacomo said.
  • To stay informed on Olympus’ upcoming product launches, news, and insights, join the waiting list at https://webonise.com/olympus/ .

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

Retrieved on: 
Tuesday, June 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Oncology, Health, Clinical Trials, Safety, Survival, Quality of life, Associate, Trial of the century, Administration, Mitomycins, Partial, Patient, OLYMPUS, Physician, Route of administration, CR, Stricture, Recurrence, Pharmaceutical industry, Nursing, Urology

Findings from the study titled, Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes, are published in the European Urology Focus online.

Key Points: 
  • Findings from the study titled, Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes, are published in the European Urology Focus online.
  • Investigators reported that the overall rate of stricture occurrence was lower with the antegrade approach (12%) compared to retrograde group (32%).
  • Partial response (PR) rates were also favorable, with 60% CR and 32% PR for antegrade administration, and 48% CR and 28% PR for retrograde administration.
  • In this study, survival outcomes are reported per patient and treatment, complications and recurrence outcomes are reported per renal unit.

China International Medical Equipment Fair 2023 Held in Shanghai in May, Showcasing Cutting-Edge Healthcare Technologies

Retrieved on: 
Monday, May 15, 2023
87th Air Base Wing, Stryker, Exhibition, Hong Kong International Medical Devices and Supplies Fair, Elective surgery, GE, SIEMENS, Rehabilitation, Endoscopy, USD, Illumina, Anesthesia, Hospital, Patient, OLYMPUS, Conditional sentence, RMB, Pharmaceutical industry

SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai.

Key Points: 
  • SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai.
  • The CMEF of this year provided visitors with products across several categories, including medical imaging, electronic medical equipment, hospital construction, medical consumables, orthopedics, rehabilitation, emergency rescue, and animal care.
  • Leading medical imaging solutions were displayed by companies such as United Image and SIEMENS.
  • Over 30 provincial governments in China have released reports highlighting initiatives to overhaul the medical sector and boost healthcare standards for both urban and rural residents.

China International Medical Equipment Fair 2023 Held in Shanghai in May, Showcasing Cutting-Edge Healthcare Technologies

Retrieved on: 
Monday, May 15, 2023
87th Air Base Wing, Stryker, Exhibition, Hong Kong International Medical Devices and Supplies Fair, Elective surgery, GE, SIEMENS, Rehabilitation, Multimedia, Endoscopy, USD, Illumina, Anesthesia, Hospital, Patient, OLYMPUS, Conditional sentence, RMB, Pharmaceutical industry

SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai.

Key Points: 
  • SHANGHAI, May 15, 2023 /PRNewswire/ -- The 87th edition of the China International Medical Equipment Fair (CMEF) has opened its door to the world in Shanghai.
  • The CMEF of this year provided visitors with products across several categories, including medical imaging, electronic medical equipment, hospital construction, medical consumables, orthopedics, rehabilitation, emergency rescue, and animal care.
  • Leading medical imaging solutions were displayed by companies such as United Image and SIEMENS.
  • Over 30 provincial governments in China have released reports highlighting initiatives to overhaul the medical sector and boost healthcare standards for both urban and rural residents.

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Ureter, American Urological Association, Society, Investment, Software, AUA, New Drug Application, Clinical trial, NDA, RNU, SUO, Mitomycins, UTUC, Patient, OLYMPUS, Physician, Guideline, RTW, Webcast, Growth, LG, Neoplasm, Conference, Safety, ATLAS, Pharmaceutical industry, Medical imaging, Video game, Bank, Mitomycin C

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments.
  • Generated net product revenue of $17.2 million for the first quarter of 2023, representing ~27% growth over the first quarter of 2022.
  • Activated sites on May 1, 2023 were 1,009, compared to 983 on March 1, 2023, while repeat accounts on May 1, 2023 were 235, compared to 214 on March 1, 2023.
  • First Quarter 2022 Financial Results:
    Jelmyto Revenue: UroGen reported net product revenue of Jelmyto for the first quarter 2023 of $17.2 million, compared to $13.6 million in the first quarter of 2022.

First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation

Retrieved on: 
Monday, May 1, 2023
Research, Surgery, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, The Journal of Urology, Safety, American Urological Association, UTUC, Stenosis, Estate (law), Adjuvant, Patient, OLYMPUS, Journal, LG, Recurrence, Bias, Treatment, Pharmaceutical industry, Nursing, Medical imaging, Urology

Early failure is a drawback for endoscopic ablation alone, which occurs in 40-50% of UTUC patients by three months.

Key Points: 
  • Early failure is a drawback for endoscopic ablation alone, which occurs in 40-50% of UTUC patients by three months.
  • Response at primary endoscopic evaluation was defined as no visual tumor or negative biopsy.
  • The rate of ureteral stenosis for those in this study who underwent complete endoscopic ablation followed by JELMYTO treatment was 23%.
  • Ureteral stenosis was defined as a condition requiring ureteral stent or nephrostomy, or that would typically warrant stent or nephrostomy.

New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis  

Retrieved on: 
Sunday, April 30, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Ureter, Urine, Stenosis, Safety, Neoplasm, Efficacy, American Urological Association, Mitomycins, UTUC, State University of New York Upstate Medical University, OLYMPUS, Patient, Kidney, LG, Abstract, Treatment, Pharmaceutical industry, Medical imaging

The study titled, First Analysis of the Safety and Efficacy of UGN-101 in the Treatment of Ureteral Tumors (Abstract PD24-07) is the first to assess JELMYTO in treating ureteral tumors.

Key Points: 
  • The study titled, First Analysis of the Safety and Efficacy of UGN-101 in the Treatment of Ureteral Tumors (Abstract PD24-07) is the first to assess JELMYTO in treating ureteral tumors.
  • The investigators reported no difference in outcomes at first endoscopic evaluation based on UTUC tumor location (ureter vs. renal pelvis) (p=0.644).
  • JELMYTO is approved for the treatment of low-grade upper tract urothelial cancer (LG-UTUC) in adult patients.
  • “These data are promising for LG-UTUC patients with ureteral tumors,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen.

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

Retrieved on: 
Thursday, March 16, 2023
Research, General Health, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Other Science, Health, Investment, Conference, RTW, Webcast, Urology, Bladder cancer, Software, Financial result, Patient, Mitomycins, Quarter, Stenosis, SUO, Growth, LIBOR, Tax, Safety, ATLAS, NDA, OLYMPUS, DOR, Neoplasm, Recurrence, Pharmaceutical industry, Nursing, Video game, Cryptocurrency, Bank, Broadcasting

Supported by a growing body of real-world outcomes data, we delivered our strongest ever JELMYTO net sales in Q4 helping propel ~34% full-year growth for fiscal 2022.

Key Points: 
  • Supported by a growing body of real-world outcomes data, we delivered our strongest ever JELMYTO net sales in Q4 helping propel ~34% full-year growth for fiscal 2022.
  • Fourth Quarter and Full Year 2022 Financial Results:
    JELMYTO Revenue: UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.
  • Research and development expenses for the full year 2022 were $52.9 million, including non-cash share-based compensation expense of $2.6 million.
  • SG&A Expense: Selling, general and administrative expenses for the fourth quarter 2022 were $21.6 million, including non-cash share-based compensation expense of $1.8 million.

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

Retrieved on: 
Wednesday, January 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Plasma protein binding, Urology, Olympus, Neoplasm, Treatment, CR, Patient, Observation, Physician, UTUC, Mitomycins, Pharmaceutical industry, Medical imaging, OLYMPUS

The study titled, “Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes,” is published in Urologic Oncology: Seminars and Original Investigations.

Key Points: 
  • The study titled, “Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes,” is published in Urologic Oncology: Seminars and Original Investigations.
  • The authors describe several trends in JELMYTO use that differ from the pivotal Olympus study that led to drug approval.
  • JELMYTO is indicated for the treatment of adult patients with low-grade upper tract urothelial cancer (LG-UTUC).
  • Almost half of the patients in the review were treated by antegrade administration of JELMYTO through a nephrostomy tube.

Binance Smart Chain Token, Hibiki Finance, Acquires Olympus Token

Retrieved on: 
Tuesday, April 26, 2022
Crypto.com, OLYMPUS, Matic, NFT, BSC, Project, Decentralized finance, Locker, Olympus, RPG, Acquisition, Blockchain, Cryptocurrency, Risk management, Cronos

Los Angeles, California--(Newsfile Corp. - April 25, 2022) - B token, Hibiki Finance, has officially acquired rival Binance Smart Chain Project, Olympus Token, further adding to their large amount of existing blockchain tools and games.

Key Points: 
  • Los Angeles, California--(Newsfile Corp. - April 25, 2022) - B token, Hibiki Finance, has officially acquired rival Binance Smart Chain Project, Olympus Token, further adding to their large amount of existing blockchain tools and games.
  • Olympus Token was a joint project spearheaded by the founders of Bingus Network, Bogged Finance and GabeCoin, with the ambitious goal of being the leading rewards token on the Binance Smart Chain network.
  • Olympus Token was the first $BUSD based rewards token, eventually generating over $1,200,000 BUSD for holders, protected by their whale buy-back system dubbed 'Zeus'.
  • Hibiki Finance, best known for their P2E GameFi project Cryptoshoujo, is a multi-chain ecosystem offering tools and services based on Binance Smart Chain, KuCoin Community Chain and Crypto.com's Cronos network.